Targeting Tissular Immune Response Improves Diagnostic Performance of Anti-Saccharomyces cerevisiae Antibodies (ASCA) in Crohn’s Disease

Daniel Bertin1,2, Jean-Charles Grimaud3, Nathalie Lesavre4, Chahine Benelmouloud1, Ariadne Desjeux3, Stéphane Garcia5, Sophie Desplat-Jégo1,2*

1 Service d’Immunologie, Pôle de Biologie, Hôpital de la Conception, Assistance Publique-Hôpitaux de Marseille, Marseille, France, 2 Aix-Marseille Université, Centre national de la recherche scientifique, Neurobiologie des Interactions Cellulaires et Neurophysiopathologie UMR 7259, Marseille, France, 3 Service de Gastroentérologie, Hôpital Nord, Assistance Publique-Hôpitaux de Marseille, Marseille, France, 4 Centre d’Investigations Cliniques, Hôpital Nord, Assistance Publique-Hôpitaux de Marseille, Marseille, France, 5 Laboratoire d’Anatomie Pathologique, Hôpital Nord, Assistance Publique-Hôpitaux de Marseille, Marseille, France

Abstract

Antibodies against Saccharomyces cerevisiae (ASCA) and Escherichia coli outer membrane porin C (anti-OmpC) are known to be detectable in the serum of patients with Crohn’s disease (CD) but display a very poor sensitivity for the disease especially in forms with isolated colonic involvement. In this study we aimed at evaluating performances of these markers in supernatant of cultured colonic biopsies. Patients with colonic CD (n = 67), ulcerative colitis (UC) (n = 35) and control individuals (n = 37) were prospectively recruited for colonoscopy pinch biopsies and blood sampling. Serum and supernatant of control tissues were analyzed for ASCA and anti-OmpC. Direct immunofluorescence was also performed on colonic tissues for total IgA detection. We detected for the first time ASCA IgA/IgG and anti-OmpC IgA in cultured colonic tissue supernatants. For both markers, sensitivities for diagnosing CD were better in supernatants (ASCA: 53.7%, anti-OmpC: 28.4%) than in serum (ASCA: 31.3%, anti-OmpC: 22.4%). Combination of results from a panel of these tests gave the greatest sensitivity ever described for CD diagnosis in colonic forms (70.2%). In this study, we described, for the first time, ASCA in supernatant of colonic tissue cultures. This assaying approach in CD diagnosis should be taken into consideration in the future especially in CD forms with isolated colonic involvement.

Introduction

Inflammatory bowel diseases (IBD) such as Crohn’s disease (CD) or ulcerative colitis (UC) are heterogeneous chronic intestinal inflammatory disorders occurring in genetically predisposed individuals in association with a host immune response against gut flora. In most cases, a diagnosis of CD or UC can be made with high certainty but sometimes and especially in case of exclusive colonic localization of the disease, the diagnosis is difficult. Several serum antibodies against microbial antigens have been proposed as serological markers for CD diagnosis [1]. Among them, anti-Saccharomyces cerevisiae antibodies (ASCA) and anti-OmpC antibodies are directed against phosphopentidomann of the cell wall of the yeast [2] and outer membrane porin C of Escherichia coli, respectively. ASCA are anti-glycan antibodies that were first described in IBD and that can be predictive for CD development in asymptomatic individuals [3]. ASCA can also be detected in patients with auto-immune diseases such as antiphospholipid syndrome, systemic lupus erythematosus where they cross-react with autoantigens [4] [5]. However in the event of IBD suspicion, ASCA reported high specificity for CD. It is now well established that ASCA could be useful for differentiating CD from UC [6]. But despite good specificity for CD, ASCA and anti-OmpC display too low sensitivities (less than 60%) for CD [6] [7] [8] [9]. In fact, especially in colonic form of CD, the situation in which serological markers should be the most relevant in order to distinguish CD from UC, the sensitivity of both test is less than 40% [10] [11]. So, the diagnostic role of these immunological markers in clinical practice appears to be limited due to this low sensitivity. Data about luminal presence of these antibodies in IBD patients are lacking. Nevertheless it could be of interest and more informative to target the local immune tissue response rather than the blood systemic response in our processes of antibody detection for CD diagnosis. We have chosen to focus our study on colonic form of CD in which serological markers offer the worst performances and for the first time we examined whether: i) ASCA and anti-OmpC can be detected in supernatants of cultured colonic pinch biopsies issued from CD patients, ii) the changing of biological fluid (supernatant versus serum) used for ASCA and anti-OmpC testing could be a simple way to improve the diagnostic role of these antibodies for CD diagnosis.
Materials and Methods

Patients

Consecutive patients suffering from IBD including CD with isolated colonic involvement or UC and control individuals undergoing colonoscopy for functional intestinal disorders without IBD were prospectively recruited for colonoscopy pinch biopsies and peripheral venous blood sampling. All patients were followed up at the gastrointestinal unit of the University Hospital in Marseille, France. The diagnosis was based on clinical, radiological, endoscopic examination and histological findings using previously described criteria [12] [13]. The disease activity of CD patients was evaluated by calculating the Crohn Disease Activity Index [14]. This study has been approved by the local ethic committee Comité de Protection des Personnes (CPP Sud Méditerranée V. All patients gave their written informed consent. The clinical trial protocol received the clinical.gov number NCT00769236. Clinical features of the diseases were collected from medical charts in clinical research forms. After serum separation, blood samples were stored at –80°C until further analysis.

Colonic biopsies cultures

During total colonoscopy under general anaesthesia, eight biopsies were performed in each part of the right, transverse and left colon. Samples were i) fixed in 4% buffered formalin for histological examination, ii) put in RPMI medium for culture technique or iii) deep frozen in liquid nitrogen then stored at –80°C for immunofluorescence technique.

For histological examination, biopsies were fixed in 4% buffered formalin and paraffin embedded. Four thick sections were performed and stained with hematoxylin and eosin for routine examination. Inflammation was assessed using the following morphological criteria: none, non-specific chronic (predominance lymphocytes and/or plasma cells), non-specific acute (predominance of polymorphonuclear cells), specific granulomatous.

After biopsy, colonic tissues put in RPMI medium on bedside were immediately transported at room temperature to the immunology laboratory. Then, they were washed 3 times with phosphate buffered saline (PBS) and transferred into 24-well culture plates (Nunc®, Naperville, IL, USA) with RPMI 1640 medium supplemented with 10% fetal bovine serum and antibiotics (penicillin 100 U/ml, streptomycin 100 µg/ml). The plates were incubated for 72 hours at 37°C in atmosphere with 5% CO2. Then supernatants were collected, centrifuged, aliquoted and stored at –80°C until analysis.

ASCA IgA /IgG detection

ASCA IgA and IgG were detected by indirect immunofluorescence (IF), in a blinded way, using a commercially available detection kit (Euroimmun, Germany). Sera were diluted in phosphate buffered saline (PBS) and transferred into 24-well culture plates (Nunc®, Naperville, IL, USA) with RPMI 1640 medium supplemented with 10% fetal bovine serum and antibiotics (penicillin 100 U/ml, streptomycin 100 µg/ml). The plates were incubated for 72 hours at 37°C in atmosphere with 5% CO2. Then supernatants were collected, centrifuged, aliquoted and stored at –80°C until analysis.

Anti-OmpC IgA detection

IgA antibodies against bacterial OmpC were detected, in a blinded way, with the commercially available ELISA test QUANTA Lite OMP PLUS® (INOVA Diagnostics, San Diego, CA, USA) according to the manufacturer’s protocol. Serum results are expressed in arbitrary units (A.U) with a cutoff for positivity of 25 A.U. Due to the lack of a manufacturer’s cutoff for supernatants we had to calculate it. We defined the cutoff for supernatants positivity as the 97th percentile of the optic density (O.D) obtained for the UC + control group. This cut off stands at 0.831 absorbance units. Reproducibility for anti-OmpC IgA detection in supernatants was calculated and the inter-assay variation coefficient reached 10.2%.

IgA detection on colonic tissues

IgA detection was carried out on 5-mm thick frozen sections (cryostat Leica CM 3050, Rueil Malmaison, France) using a direct immunofluorescence technique. The procedure was realized using an FITC conjugated F(ab)2 recognizing human IgA (Biorad, Marnes-la-Coquette, France) diluted at 1:40 and incubated 30 min at room temperature. IgA deposits were assessed and described as linear or granular and located in epithelial cells or in stromal compartment.

Statistical analysis

Sensitivity was measured as the probability of a positive result in a patient with CD; specificity was measured as the probability of a negative result in a patient with UC or non IBD intestinal disorders (control group). The positive predictive value (PPV) was the probability of having CD and a positive result while the negative predictive value (NPV) was the probability of having UC or non IBD intestinal disorders and negative result. Comparison of different groups was done using the Chi-square test or Fisher’s exact test when appropriate. The agreement between ASCA and anti-OmpC detection in both sera and supernatants was evaluated using Cohen’s Kappa coefficient [15] which takes on the value i) zero if there is no more agreement between two tests as can be expected on the basis of chance, ii) 1 if there is perfect agreement. It is considered that Kappa values lower than 0.4 represent poor agreement, values between 0.4 and 0.80 moderate to substantial agreement, and values higher than 0.80 almost perfect agreements. Negative Kappa indicates the level of agreement was below that expected by chance. Data were analyzed using Graphpad Prism 5 (Graphpad software, San Diego, CA, USA) and the threshold for statistical significance was set at p<0.05.

Results

Patient population

We prospectively and consecutively included a total of 139 patients: 67 CD patients with isolated colonic involvement, 35 patients with UC and 37 control individuals undergoing colonoscopy for functional intestinal disorders without IBD. The median age at study was 43.4 [19–84] for CD group, 42.9 [18–74] for UC group and 58.1 [22–79] for the control group. The sex ratios (M/F) were respectively 24/43, 20/15 and 17/20 for CD, UC and control group. The positive predictive value (PPV) was measured as the probability of a positive result in a patient with CD; specificity was measured as the probability of a negative result in a patient with UC or non IBD intestinal disorders (control group). The median age at study was 43.4 [19–84] for CD group, 42.9 [18–74] for UC group and 58.1 [22–79] for the control group. The sex ratios (M/F) were respectively 24/43, 20/15 and 17/20 for CD, UC and control group.

Among CD patients, the diagnosis of CD was set under the age of 20 years for 13 patients (19.4%) and beyond the age of 20 years for 54 patients (80.6%) and so the duration of disease was superior for 5 years for 60 patients (89.6%). The disease was active for 12 patients (17.9%) and quiescent for 55 patients (82.1%) at the time of the study. A minority of CD patients smoked (46.3%) and 36.5% had yet suffered from extra intestinal symptoms of the disease.

At the time of study, a macroscopic inflammation at colonoscopy was detected in 28 patients (41.8%). Histological findings available in only 35 CD patients showed epithelioid granuloma in 11% of patients.
Prevalence of ASCA and anti-OmpC in patient serum

Serum ASCA (IgA and/or IgG) but not anti-OmpC were statistically more prevalent \( (p = 0.003) \) in CD group than in UC + control group (Fig 1A-1B). Moreover, anti-OmpC titers were significantly higher in CD group than in UC + control group \( (p < 0.0001) \) (Fig 1C). In our population (colonic form), sensitivity and specificity of serum ASCA for CD were respectively 31.3% and 90.3% while for anti-OmpC (IgA) we found sensitivity at 22.4% and specificity at 90.3% for CD (Table 1).

**Table 1. Serological prevalence of ASCA and anti-OmpC in CD and UC patients.**

|          | CD    | UC    | Controls | p     |
|----------|-------|-------|----------|-------|
| Serum ASCA (IgA and/or IgG) | 21    | 5     | 2        | 0.003 |
| Serum anti-OmpC (IgA) | 46    | 30    | 35       | <0.0001|
| Supernatant ASCA (IgA and/or IgG) | 36    | 7     | 4        | <0.0001|
| Supernatant anti-OmpC (IgA) | 31    | 28    | 33       | <0.0001|

Prevalence of ASCA and anti-OmpC in colonic culture supernatants

We showed for the first time that ASCA (IgA and/or IgG) and anti-OmpC (IgA) were detectable in colonic tissue culture supernatants. We found ASCA in 36/67 CD supernatants and anti-OmpC in 19/67 (Fig 1A-1B). ASCA and anti-OmpC were statistically more prevalent \( (p < 0.0001) \) in CD group than in UC + control group. Among 36 CD patients with ASCA in supernatant, we found that 15 of them (41.7%) displayed both ASCA IgA and IgG, 14 patients (38.9%) only displayed ASCA IgA and 7 patients (19.4%) only displayed ASCA IgG.

Comparative performances of ASCA and anti-OmpC for CD diagnosis in serum versus culture supernatants

Nineteen ASCA seronegative CD patients were positive for ASCA in culture supernatant. Among ASCA negative CD patients, 7 were anti-OmpC positive in serum (2 patients) or in culture supernatant (5 patients) (Figure 2). We have not found any patient simultaneously positive for the four tests (Figure 2). Among 67 patients with CD, 20 patients remained negative for ASCA and anti-OmpC whatever the analyzed sample (serum or supernatants) (Figure 2).

ASCA sensitivity for CD diagnosis was higher with supernatants (53.7%) than with serum (31.3%). This increase of sensitivity

**Figure 1. ASCA and anti-OmpC detection in sera and supernatants for each clinical group.** (A) Qualitative results of anti-Saccharomyces cerevisiae antibodies (ASCA) test by IFI in sera and supernatants for each clinical group. One patient is considered as ASCA positive in case of positivity of ASCA IgA and/or ASCA IgG. (B) Anti-outer membrane porine C antibodies (anti-OmpC) detection by ELISA in sera and supernatants for each clinical group. (C) Distribution of anti-OmpC antibody levels in patient sera. According to manufacturer recommendations, anti-OmpC antibody levels obtained with ELISA are considered as significant when superior or equal to 25 arbitrary units (A.U). (D) Distribution of optical densities (O.D) obtained with anti-OmpC ELISA in patient supernatants issued from culture of colonic tissues. The threshold of positivity (0.831 absorbance units) is the 97th centile of the O.D obtained for the controls + UC group. NS: no statistically significant difference. The comparison between different groups is done using the Student’s t-test with \( p = 0.05 \) as significance level. CD: Crohn’s disease, UC: ulcerative colitis, Controls: patients suffering from functional intestinal disorders but not from CD or UC.
Table 1. Performances of ASCA and anti-OmpC tests.

| Test combination | Se (%) | Sp (%) | PPV (%) | NPV (%) |
|------------------|--------|--------|---------|---------|
| Serum ASCA       | 31.3   | 90.3   | 75      | 58.6    |
| Serum OmpC       | 22.4   | 90.3   | 68.2    | 55.6    |
| Supernatant ASCA | 53.7   | 84.7   | 76.6    | 66.3    |
| Supernatant OmpC | 28.4   | 93.1   | 79.2    | 58.3    |

Table 1. Performances of ASCA and anti-OmpC tests.

| Test combination | Se (%) | Sp (%) | PPV (%) | NPV (%) |
|------------------|--------|--------|---------|---------|
| Serum ASCA       | 59.7   | 79.8   | 72.7    | 67.9    |
| and supernatant ASCA | 46.3   | 86.1   | 75.6    | 63.3    |
| Serum OmpC       | 41.8   | 82     | 68.3    | 60.2    |
| and supernatant OmpC | 64.2   | 79.2   | 74.1    | 70.4    |
| Serum ASCA       | 70.2   | 69.4   | 68.1    | 71.4    |
| and supernatant ASCA | 31.3   | 90.3   | 75      | 58.6    |
| and supernatant OmpC | 64.3   | 86.1   | 75.6    | 63.3    |

ASA: Anti-Saccharomyces cerevisiae antibodies, anti-OmpC: anti-outer membrane porine C antibodies, Se: sensitivity, Sp: specificity, PPV: positive predictive value, NPV: negative predictive value all expressed in percents.
doi:10.1371/journal.pone.0080433.t001

Study of relationship between IgA intestinal deposit and ASCA/anti-OmpC antibody detection in supernatants

Biopsies issued from 61 patients (twenty nine CD patients and thirty-two patients from UC + control group) were analyzed by direct immunofluorescence for studying total IgA colonic deposits. We visualized granular IgA deposits in colonic mucosa both in epithelium and in stroma in all clinical groups. In fact, we observed no significant relationship between IgA colonic deposits and i) the diagnosis of CD or ii) ASCA/anti-OmpC antibody detection in supernatants (Table 2). In fact, we could detect IgA deposits on control patients and we did not find any staining in several CD patients even though they were positive for ASCA IgA in culture supernatants.

Study of correlation between ASCA or anti-OmpC detection and CD patient features

As showed in Table 3, serum ASCA antibodies were more frequent in men than in women (p = 0.014). Nevertheless, we did not find any correlation between ASCA positivity in serum and/or supernatant and the other studied clinical features (age at sampling, smoking, disease duration, macroscopic inflammation at colonoscopy, epithelium granuloma, extra intestinal symptoms and treatment). In our CD cohort, we did not find any correlation between anti-OmpC positivity and the studied clinical features (Table 4).

Discussion

In the present study, we assessed the clinical value of ASCA and anti-OmpC tests performed in supernatant issued from cultured colonic biopsies for the diagnosis of CD in comparison with their detection in serum. Moreover, to our knowledge this work is the first study focusing on colonic form of CD.

We described here for the first time the detection of ASCA IgA/ IgG and anti-OmpC IgA in cultured colonic tissue supernatants. Moreover we found that these markers were significantly more prevalent in CD patient group than in UC + controls group. In our colonic CD population, the correlation study between the presence of these markers and various clinical features has only shown a greater prevalence of serum ASCA in men than in women. For both markers, sensitivities for diagnosing CD were greatly better in supernatants (ASCA: 53.7%, anti-OmpC: 28.4%) than in serum (ASCA: 31.3%, anti-OmpC: 22.4%) especially for ASCA. Combining results from a panel of these tests gave the greatest ASCA sensitivity ever described for CD diagnosis in colonic forms (70.2%).

It is now widely accepted that defects in innate immunity cause a loss of the mucosal tolerance to microbial components [16]. Moreover, in the latter decades, various antibodies against microbial epitopes have been studied in CD and UC but many of these studies concluded that these serological markers were of poor diagnostic interest by a great lack of sensitivity for CD [17]. In fact all these studies were searching markers in the blood only and did not focus on intestinal tissue which is the main place where IBD disorders occur. We suggest here that the poor performances of these markers are related to the lack of consideration for the immune local response occurring in the intestinal tissue. In such context, an interesting approach has been proposed by Carroccio et al [18] who detected anti-endomysial antibodies in cultured duodenal mucosa biopsy from celiac patients. However, to our knowledge, there are no studies that performed mucosal intestinal biopsies to verify if ASCA and anti-OmpC are detectable in culture supernatant. We have showed here that ASCA and anti-OmpC from both isotypes IgA and IgG could be detected from colonic tissue cultures. Nevertheless, the detection of IgA in culture supernatant brings up questions about the origin of these IgA. In fact the presence or not of a secretory piece in the detected IgA remains to be determined since the conjugate we used in routine was not targeted against this component. Indeed secretory IgA containing a secretory piece may be of intestinal origin. A further analysis with an antibody targeting secretory piece should be of interest. Moreover, the IgA assayed in the supernatant may be related to biopsy contamination by blood or mucus but the fact that we have rinsed the tissues several times before IIF test seems to exclude this hypothesis. The origin of this IgA secretion remains uncertain but isolated lymphoid follicles can be found in the colon and it has been shown that their number, diameter and density increase in inflammatory conditions such as IBD [19]. ILF are gut-associated lymphoid tissues that are supposed to play a role in immune surveillance and colonic repair mechanisms [20]. These lymphoid follicles as well as Peyers’ patches of the small intestine contains numerous dendritic cells, macrophages, T and B cells and could be a source for the IgA detected in the supernatants of cultured colonic biopsies. Whatever the origin of this IgA secretion, we suggest that it could be a very localized and intermittent phenomenon since i) among 3 biopsies done per patient, there is often only one which gives a positive result, ii) the
Dubinsky [26] studied a pediatric cohort of 196 patients with CD with the clinical interest of anti-OmpC in serum of CD patients. Literature data are now lacking. Moreover, only a few studies deal isolated colonic involvement and no pediatric case have been included. For this particular cohort of CD, to our knowledge, perianal disease and requirement for surgery in CD. In a previous study [25] we agreed with some of these data but in the present study [24] [10] and it has also been observed for anti-OmpC [7]. Two recent meta-analyses preferentially associated with ileal forms of CD [24] [10] and it has also been observed for anti-OmpC [7]. Two recent meta-analyses preferentially associated with ileal forms of CD [24].

Our results showed also that ASCA and anti-OmpC detection in culture supernatant improved the sensitivity of ASCA in culture supernatants for the detection of CD patients. In our study, we were able to detect 19 patients who were not detected by these assays performed in serum alone: 9 were positive for ASCA, 5 for anti-OmpC and 5 for both tests in supernatants. By using tests in supernatants we were then able to successfully commute the CD biological marker status in 19 out of 67 patients.

Antineutrophil cytoplasmic antibodies (ANCA) were also investigated in sera and supernatants but we didn’t detect any ANCA by IIF in supernatants of cultured colonic biopsies (data not shown) thus there is no interest of searching them in culture supernatants.

However, our results showed also that ASCA and anti-OmpC detection in culture supernatant improved the sensitivity of ASCA and anti-OmpC for the detection of CD patients. In our study, we were able to detect 19 patients who were not detected by these assays performed in serum alone: 9 were positive for ASCA, 5 for anti-OmpC and 5 for both tests in supernatants. By using tests in supernatants we were then able to successfully commute the CD biological marker status in 19 out of 67 patients.

We did not reveal a link between the presence of these markers and CD activity at the time of completion of sampling. The lack of relationship between disease activity and the presence of positive sample was not necessarily the sample recovered from a macroscopically inflammatory area, iii) the amount of produced IgA are low and requires to work with undiluted supernatants. In a recent and interesting study, Tang et al [21] have shown that ASCA could be detected in feces suggesting that ASCA could be excreted. To better investigate the origin of the IgA detected in our supernatants we have performed in parallel direct immunofluorescence on the studied colonic tissue. We found then no difference between control and CD cohort: in both populations, we could detect IgA deposits in colonic mucosa and they were not associated with the presence or not of ASCA in supernatants. Nevertheless we have only studied the total IgA contingent since, for technical reasons, we were not able to distinguish ASCA IgA among total IgA. Then we can’t exclude that ASCA IgA deposits are more frequent during CD than UC.

ASCA and anti-OmpC are serological markers that have been proposed to differentiate CD from UC. Previous studies showed that serum ASCA specificity for CD is almost 95% while sensitivity is low since high titers of ASCA IgG and/or IgA were found in only 50–70% of all CD patients [22] [23] and less than 40% in colonic form of the disease. In our study we have chosen to work only on CD with isolated colonic involvement in order to target the population of CD patients in which serological test could be the most relevant and helpful. So it is not surprising to obtain in our hands a sensitivity of 31.3% for ASCA test and 22.4% for anti-OmpC test in serum. In fact the expression of ASCA in serum is preferentially associated with ileal forms of CD [24] [10] and it has also been observed for anti-OmpC [7]. Two recent meta-analyses [6] [9] indicated that positive ASCA serum status is associated with early-onset age, ileal involvement, complicated behavior, perianal disease and requirement for surgery in CD. In a previous study [25] we agreed with some of these data but in the present study we highlighted the specificities of a CD patient cohort with isolated colonic involvement and no pediatric case have been included. For this particular cohort of CD, to our knowledge, literature data are now lacking. Moreover, only a few studies deal with the clinical interest of anti-OmpC in serum of CD patients. Dubinsky [26] studied a pediatric cohort of 196 patients with CD and showed that the positivity of anti-OmpC in serum was associated with a more severe form of the disease. Papp [8] and Ferrante [7] showed that CD adult patients with anti-OmpC positive had more often surgery than those who were anti-OmpC negative. They also observed that the positivity of anti-OmpC in serum of patients with CD was more frequently associated with long-term evolution of the disease and early age diagnosis. However, we have not made such observations in our CD population for anti-OmpC as well as in serum as in supernatants even if we have used the same reagents. One explanation could be that Papp and Ferrante have not distinguished the colonic form of CD from the others in their correlation study with clinical features.

Table 2. Study of IgA intestinal deposit and ASCA/anti-OmpC antibody detection in supernatants for each clinical group.

|                        | IgA colonic deposit by DIF coefficient | Kappa coefficient |
|------------------------|---------------------------------------|-------------------|
|                        | +                                    | -                 |
| IgA ASCA supernatants  | +                                    | 15                |
|                        | -                                    | 2                 |
|                        | -                                   | -0.13             |
| CD (n = 29)            | IgA anti-OmpC supernatants           | +                 |
|                        | +                                    | 7                 |
|                        | -                                    | 0                 |
|                        | -20                                 | 2                 |
| Controls (n = 32)      | IgA ASCA supernatants                | +                 |
|                        | +                                    | 4                 |
|                        | -                                    | 0                 |
|                        | +                                   | 28                |
| UC                     | IgA anti-OmpC supernatants           | +                 |
|                        | +                                    | 2                 |
|                        | -30                                 | 0                 |

IgA intestinal deposit was evaluated by indirect immunofluorescence (IIF). The agreement between IgA intestinal deposit and ASCA / anti-OmpC antibody detection in supernatants of each clinical group was evaluated using Cohen’s kappa coefficient. ASCA: Anti-Saccharomyces cerevisiae antibodies, anti-OmpC: anti-outer membrane porine C antibodies, anti-OmpC: anti-outer membrane porine C antibodies.
antibodies is in favor of the absence of a direct pathogenic role of these antibodies. It should also be noted that we only measured the IgA anti-OmpC (IgG isotype not commercially available) while ASCA were evaluated for both IgA and IgG isotypes. This difference may explain in part the greater sensitivity of ASCA for CD compared to anti-OmpC. Further studies could evaluate the performance gain of IgG anti-OmpC since the first highlighted anti-OmpC antibody was IgG isotype [28].

We also evaluated the interest of a combination of tests ASCA / anti OmpC performed in the serum and/or in the supernatant. For both ASCA and anti-OmpC, supernatants analysis added to serum result, significantly increases the sensitivity of the tests: ASCA gains 28.4% sensitivity and anti-OmpC gains 23.9% sensitivity. By using a combination Serum ASCA and/or ASCA supernatant and/or OmpC serum the sensitivity amounted to 62.7%, which is slightly more than the 59.7% sensitivity of the combination ASCA serum and/or ASCA supernatant: the value of serum anti-OmpC appears here limited. Finally, if we combine results issued from the four possible tests (ASCA serum and/or ASCA supernatant and/or OmpC serum and/or OmpC supernatant) we reach the maximum sensitivity (70.2%). This improvement compared to ASCA alone sensitivity (serum or supernatant) is due to the fact that among the population with CD (n = 67) we found 7 patients who were positive for anti-OmpC only. Despite these results combinations, 20 of 67 patients with CD (29.8%) were still negative for both tests (ASCA and anti-OmpC) in both

Table 3. Study of correlation between ASCA status and CD clinical features.

| Clinical features of CD                  | Number of patients (%) | Serum ASCA + (%) | p  | Supernatant ASCA + (%) | p   |
|----------------------------------------|------------------------|------------------|----|------------------------|-----|
| Gender                                 |                        |                  |    |                        |     |
| Men                                    | 24 (35.8)              | 12 (50)          | 0.014 | 15 (63)              | NS  |
| Women                                  | 43 (64.2)              | 9 (21)           |     | 21 (49)               |     |
| Age at sampling                        |                        |                  |    |                        |     |
| > 40 yrs                               | 38 (56.7)              | 12 (32)          | NS  | 23 (61)               | NS  |
| < 40 yrs                               | 29 (43.3)              | 9 (31)           |     | 13 (45)               |     |
| Disease activity                       |                        |                  |    |                        |     |
| Active                                 | 12 (17.9)              | 6 (50)           | NS  | 6 (50)                | NS  |
| Quiescent                              | 55 (82.1)              | 15 (27)          |     | 30 (55)               |     |
| Age at diagnosis                       |                        |                  |    |                        |     |
| > 20 yrs                               | 54 (80.6)              | 16 (30)          | NS  | 29 (54)               | NS  |
| < 20 yrs                               | 13 (19.4)              | 5 (38)           |     | 7 (54)                |     |
| Duration of disease                    |                        |                  |    |                        |     |
| > 5 yrs                                | 60 (89.6)              | 20 (33)          | NS  | 34 (57)               | NS  |
| < 5 yrs                                | 7 (10.4)               | 2 (29)           |     | 2 (29)                |     |
| Smoking                                |                        |                  |    |                        |     |
| Yes                                    | 31 (46.3)              | 11 (35)          | NS  | 16 (52)               | NS  |
| No                                     | 36 (53.7)              | 10 (28)          |     | 20 (56)               |     |
| Macroscopic Inflammation at colonoscopy at inclusion |  |                  |    |                        |     |
| Presence                               | 28 (41.8)              | 12 (43)          | NS  | 16 (57)               | NS  |
| Absence                                | 39 (58.2)              | 9 (23)           |     | 20 (51)               |     |
| Epithelioid granulomas                 |                        |                  |    |                        |     |
| Presence                               | 4 (11.4)               | 3 (75)           | NS  | 3 (75)                | NS  |
| Absence                                | 31 (88.6)              | 7 (23)           |     | 17 (55)               |     |
| Extra-intestinal symptoms              |                        |                  |    |                        |     |
| Presence                               | 23 (36.5)              | 6 (26)           | NS  | 10 (43)               | NS  |
| Absence                                | 40 (63.5)              | 12 (30)          |     | 22 (56)               |     |
| Digestive surgery                      |                        |                  |    |                        |     |
| Yes                                    | 35 (52.2)              | 14 (40)          | NS  | 23 (64)               | NS  |
| No                                     | 32 (47.8)              | 7 (22)           |     | 13 (41)               |     |
| Medical treatment                      |                        |                  |    |                        |     |
| Yes                                    | 43 (64.2)              | 13 (30)          | NS  | 23 (53)               | NS  |
| No                                     | 24 (35.8)              | 8 (33)           |     | 13 (54)               |     |

ASCA: Anti-Saccharomyces cerevisiae antibodies, CD: Crohn disease, NS: no statistically significant difference. The comparison of different groups is done using the chi-square test or Fisher’s exact test when appropriate with p < 0.05 as significance level. doi:10.1371/journal.pone.0080433.t003
matrices (serum and supernatant). The degree of agreement between the results of ASCA and anti-OmpC is poor (Kappa = 0.033 in serum and Kappa = 0.165 in the supernatant) which means that these two tests are not substitutable. Nevertheless, such a combination is expensive so, in our opinion, the contribution of anti-OmpC is negligible and does not justify its implementation in routine. Given the improvement of sensitivity of ASCA test by analyzing culture supernatant, we propose to use this test in immunological laboratories equipped for tissue cultures for helping diagnosis of CD.

### Author Contributions

Conceived and designed the experiments: JCG NL SDJ. Performed the experiments: CB DB SDJ SG. Analyzed the data: DB NL SDJ. Contributed reagents/materials/analysis tools: AD JCG NL. Wrote the paper: DB SDJ.

### References

1. Prideaux L, De Cruz P, Ng SC, Kamm MA (2012) Serological antibodies in inflammatory bowel disease: a systematic review. Inflamm Bowel Dis 18: 1340-1355. doi:10.1002/ibd.21903.

2. Sendid B, Colombel JF, Jacquiniot PM, Faille C, Fruit J, et al. (1996) Specific antibody response to oligomannosidic epitopes in Crohn's disease. Clin Diagn Lab Immunol 3: 219-226.

---

**Table 4. Study of correlation between anti-OmpC antibodies status and CD clinical features.**

| Clinical features of CD                  | Number of patients (%) | Serum OmpC + (%) | p   | Supernatant OmpC + (%) | p   |
|-----------------------------------------|-----------------------|------------------|-----|------------------------|-----|
| **Gender**                              |                       |                  |     |                        |     |
| Men                                     | 24 (35.8)             | 8 (33)           | NS  | 9 (38)                 | NS  |
| Women                                   | 43 (64.2)             | 7 (16)           |     | 10 (23)                |     |
| **Age at sampling**                     |                       |                  |     |                        |     |
| > 40 yrs                                | 38 (56.7)             | 10 (26)          | NS  | 12 (32)                | NS  |
| < 40 yrs                                | 29 (43.3)             | 5 (17)           |     | 7 (24)                 |     |
| **Disease activity**                    |                       |                  |     |                        |     |
| Active                                  | 12 (17.9)             | 4 (33)           | NS  | 5 (42)                 | NS  |
| Quiescent                               | 55 (82.1)             | 11 (20)          |     | 14 (25)                |     |
| **Age at diagnosis**                    |                       |                  |     |                        |     |
| > 20 yrs                                | 54 (80.6)             | 12 (22)          | NS  | 14 (26)                | NS  |
| < 20 yrs                                | 13 (19.4)             | 3 (23)           |     | 5 (38)                 |     |
| **Duration of disease**                 |                       |                  |     |                        |     |
| > 5 yrs                                 | 60 (89.6)             | 14 (23)          | NS  | 17 (28)                | NS  |
| < 5 yrs                                 | 7 (10.4)              | 1 (14)           |     | 2 (29)                 |     |
| **Smoking**                             |                       |                  |     |                        |     |
| Yes                                     | 31 (46.3)             | 5 (16)           | NS  | 10 (32)                | NS  |
| No                                      | 36 (53.7)             | 10 (28)          |     | 9 (25)                 |     |
| **Macroscopic inflammation**            |                       |                  |     |                        |     |
| at colonoscopy at inclusion             |                       |                  |     |                        |     |
| Presence                                | 28 (41.8)             | 9 (32)           | NS  | 9 (32)                 | NS  |
| Absence                                 | 39 (58.2)             | 6 (15)           |     | 10 (26)                |     |
| **Epithelioid granulomas**              |                       |                  |     |                        |     |
| Presence                                | 4 (11.4)              | 0 (0)            | NS  | 2 (50)                 | NS  |
| Absence                                 | 31 (88.6)             | 10 (32)          |     | 6 (19)                 |     |
| **Extra-intestinal symptoms**           |                       |                  |     |                        |     |
| Presence                                | 23 (36.5)             | 5 (22)           | NS  | 6 (26)                 | NS  |
| Absence                                 | 40 (63.5)             | 10 (25)          |     | 12 (30)                |     |
| **Digestive surgery**                   |                       |                  |     |                        |     |
| Yes                                     | 35 (52.2)             | 9 (26)           | NS  | 13 (37)                | NS  |
| No                                      | 32 (47.8)             | 6 (19)           |     | 6 (19)                 |     |
| **Medical treatment**                   |                       |                  |     |                        |     |
| Yes                                     | 43 (64.2)             | 9 (21)           | NS  | 13 (30)                | NS  |
| No                                      | 24 (35.8)             | 6 (25)           |     | 6 (25)                 |     |
ASCA in Culture Supernatant of Colonic Biopsies

3. Israeli E, Grottio I, Gilburd B, Balicer RD, Goldin E, et al. (2005) Anti-Saccharomyces cerevisiae and anti-neutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease. Gut 54: 1232–1236. doi:10.1136/gut.2004.060228.

4. Krings L, Blank M, Cervera R, Font J, Matthews T, et al. (2007) Cross-reactive epitopes on beta2-glycoprotein-I and Saccharomyces cerevisiae in patients with the antiphospholipid syndrome. Ann N Y Acad Sci 1108: 481–488.

5. Rinaldi M, Perricone R, Blank M, Perricone C, Shoenefeld Y (2013) Anti-Saccharomyces cerevisiae Autoantibodies in Autoimmune Diseases: from Bread Baking to Autoimmunity. Clin Rev Allergy Immunol 45: 152–161. doi:10.1007/s12016-012-8344-9.

6. Kaul A, Hultless S, Liu L, Bayless TM, Marohn MR, et al. (2012) Serum anti-glycan antibody biomarkers for inflammatory bowel disease diagnosis and progression: a systematic review and meta-analysis. Inflamm Bowel Dis 18: 1872–1884. doi:10.1002/ibd.22962.

7. Ferrante M, Herckxerts L, Joossens M, Pierik M, Joossens S, et al. (2007) New serological markers in inflammatory bowel disease are associated with complicated disease behaviour. Gut 56: 1394–1403. doi:10.1136/gut.2006.100843.

8. Papp M, Alterovitz I, Dotan N, Palatka K, Foldi I, et al. (2008) New serological markers for inflammatory bowel disease are associated with earlier age at onset, complicated disease behavior, risk for surgery, and NOD2/CARD15 genotype in a Hungarian IBD cohort. Am J Gastroenterol 103: 663–681. doi:10.1111/j.1572-0241.2007.01652.x.

9. Zhang Z, Li C, Zhao X, Lv C, He Q, et al. (2012) Anti-Saccharomyces cerevisiae antibodies associate with phenotypes and higher risk for surgery in Crohn’s disease: a meta-analysis. Dig Dis Sci 57: 2944–2954. doi:10.1007/s10620-012-2214-y.

10. Walker LJ, Aihouss MS, Drummond HE, Smith BRK, Nimmo ER, et al. (2012) Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease. World J Gastroenterol WJG 17: 1666–1673. doi:10.3748/wjg.v17.i13.1666.

11. Reumaux D, Sendid B, Navaneethan U, Boone JH, Rhodes SJ, et al. (2012) Utility of fecal and serum anti-Saccharomyces cerevisiae antibodies in the diagnosis of Crohn’s disease: like the condition of the pouch. Int J Crohns Colitis 27: 1453–1463. doi:10.1053/j.gastro.2011.02.012.

12. Abraham C, Medzhitov R (2011) Interactions between the host innate immune system and microbes in inflammatory bowel disease. Gastroenterology 140: 1729–1737. doi:10.1053/j.gastro.2011.02.012.

13. Reumaux D, Sendid B, Poulain D, Duhaillé P, Desvi O, et al. (2003) Serological markers in inflammatory bowel diseases. Best Pract Res Clin Gastroenterol 17: 19–35.

14. Vasiliauskas EA, Kam LY, Karp LC, Gaiennie J, Yang H, et al. (2000) Markers of inflammatory bowel disease. Gastroenterology 115: 822–829.

15. Israeli E, Grotto I, Gilburd B, Balicer RD, Goldin E, et al. (2005) Higher titers of anti-Saccharomyces cerevisiae antibodies IgA and IgG are associated with more complicated disease behavior. Gut 54: 1232–1236. doi:10.1136/gut.2004.060228.

16. Abraham C, Medzhitov R (2011) Interactions between the host innate immune system and microbes in inflammatory bowel disease. Gastroenterology 140: 1729–1737. doi:10.1053/j.gastro.2011.02.012.

17. Reumaux D, Sendid B, Poulain D, Duhaillé P, Desvi O, et al. (2003) Serological markers in inflammatory bowel diseases. Best Pract Res Clin Gastroenterol 17: 19–35.

18. Vasiliauskas EA, Kam LY, Karp LC, Gaiennie J, Yang H, et al. (2000) Marker antibody expression stratifies Crohn’s disease into immunologically homogeneous subgroups with distinct clinical characteristics. Gut 47: 487–496.

19. Dubinsky MC, Lin Y-C, Dutridge D, Picornell Y, Landers CJ, et al. (2006) Serum immune responses predict rapid disease progression among children with Crohn’s disease: immune responses predict disease progression. Am J Gastroenterol 101: 360–367. doi:10.1111/j.1572-0241.2006.00436.x.

20. Petersen AM, Schou C, Møllerpaas H, Engberg J, Friis-Møller A, et al. (2012) Seroreactivity to E. coli outer membrane protein C antibodies in active inflammatory bowel disease; diagnostic value and correlation with phylogroup B2. Scand J Gastroenterol 47: 153–161. doi:10.3109/00395928.2011.639090.

21. McNamara DG, Shapira D, Miller S, Davis B, et al. (2000) Colon cancer express an ulcerative colitis pANCA-related protein epitope. Infect Immun 68: 1542–1548.